December.17.2021
We advised Avilex Pharma ApS (Avilex), a clinical-stage biotechnology company developing innovative medicines for neurological disorders, on its strategic partnership with Simcere Pharmaceutical Group Ltd. (Simcere) to develop and commercialize Avilex’ lead program AVLX144 in Greater China.
The agreement grants Simcere an exclusive regional license to develop and commercialize AVLX-144, Avilex’s Phase 2-ready dimeric PSD-95 inhibitor, for the treatment of acute ischemic stroke (AIS) and other neurological conditions, as well as access to certain of the company’s library of early peptide candidates.
The Orrick team advising Avilex included David Schulman, Daniel Kadin and Eric Wall.